Lucid Diagnostics’ (LUCD) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research note published on Wednesday,Benzinga reports. They currently have a $2.00 price objective on the stock.

Other research analysts also recently issued research reports about the company. Ascendiant Capital Markets cut their target price on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Needham & Company LLC raised their price objective on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the company a “buy” rating in a research report on Monday, March 24th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $3.40.

Lucid Diagnostics Price Performance

NASDAQ:LUCD opened at $1.58 on Wednesday. Lucid Diagnostics has a 1 year low of $0.63 and a 1 year high of $1.63. The stock’s fifty day moving average price is $1.27 and its two-hundred day moving average price is $1.01. The company has a market cap of $93.76 million, a P/E ratio of -1.39 and a beta of 1.34.

Institutional Trading of Lucid Diagnostics

A number of large investors have recently modified their holdings of the business. Sargent Investment Group LLC purchased a new stake in Lucid Diagnostics in the fourth quarter valued at approximately $442,000. LPL Financial LLC increased its holdings in shares of Lucid Diagnostics by 29.1% in the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after buying an additional 12,035 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after buying an additional 65,964 shares in the last quarter. Lido Advisors LLC lifted its holdings in shares of Lucid Diagnostics by 40.0% during the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in Lucid Diagnostics in the fourth quarter worth $98,000. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.